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a b s t r a c t
Arginase-induced L-arginine deprivation is emerging as a key mechanism for the downreg-
ulationof immune responses.Wehypothesised that arginase activity increaseswithdisease
severity in HIV-seropositive patients. Our results show that peripheral blood mononuclear
cells (PBMCs) from23HIV-seropositive patientswith lowCD4+ T cell counts (≤350 cells/l)
expressed signiﬁcantly more arginase compared with 21 patients with high CD4+ T celleywords:
IV
mmune response
cells
D4 cell count
rginase
counts. Furthermore,we founda signiﬁcant associationbetween the twoprincipal prognos-
ticmarkers used tomonitor HIV disease (CD4+ T cell count and plasma viral load) and PBMC
arginase activity in antiretroviral therapy naïve patients but not in patients undergoing
therapy.
Crown Copyright © 2010 Published by Elsevier Ltd on behalf of Royal Society of
 Tropical Medicine and Hygiene. All rights reserved.-arginine
. Introduction
HIV results in a chronic infection that progressively
mpairs the immune system. Although depletion of CD4+ T
ells explainsmuch of the immunosuppression, the precise
echanisms involved in the onset of immunopathology
uring HIV infection have not yet been resolved.1
The metabolism of L-arginine by arginase is emerg-
ng as a crucial mechanism for the regulation of immune
esponses. L-arginine has two principal metabolic fates;
ither it can be metabolised by nitric oxide synthase
nto nitric oxide or by arginase into ornithine and urea.
 Based on a presentation to the Royal Society of Tropical Medicine and
ygiene Research in Progress Meeting on 16 December 2009. This poster
resentation was awarded second prize at the meeting.
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035-9203/$ – see front matter. Crown Copyright © 2010 Published by Elsevier Ltd on
oi:10.1016/j.trstmh.2010.08.004Arginase has been shown to impair T cell responses by
reducing the bioavailability of L-arginine: high arginase
activity expressed by myeloid cells results in reduced
availability of extracellular L-arginine in themicroenviron-
ment. In turn, this decrease in L-arginine results in T cell
hyporesponsiveness.2–4
To test the hypothesis that arginase activity is increased
in HIV-seropositive (HIV+) patients and might contribute
to immune dysfunction and disease progression we mea-
sured the levels of arginase activity in peripheral blood
mononuclear cells (PBMCs) isolated from the blood of HIV+
patients.
2. Materials and methodsThe duration of the study was from February 2008 to
December 2009 and a cohort of 44 HIV+ patients was
recruited from St Mary’s Hospital, London UK. Inclusion
criteria were (i) HIV+ by standard laboratory tests and (ii)
older than 18 years. From the patient’s hospital records
 behalf of Royal Society of Tropical Medicine and Hygiene. All rights reserved.
y of Tropical Medicine and Hygiene 104 (2010) 746–748 747
Figure 1. Arginase activity in peripheral bloodmononuclear cells isolated
from44HIV-seropositivepatients. (A)Arginaseactivity in21patientswith
CD4+ T cell count >350 cells/l and 23 patients with CD4+ T cell countT.E. Cloke et al. / Transactions of the Royal Societ
it was determined whether the patient was receiving
antiretroviral therapy (ART). All subjects gave written,
informed consent before participation.
Plasma HIV-I viral RNA was quantiﬁed (Bayer Quan-
tiplex assay; Bayer Diagnostics, East Walpole, MA, USA).
The standard T lymphocyte markers, CD3, CD4 and CD8
were determined by ﬂow cytometry.
Twenty millilitres of anticoagulated peripheral blood
was collected in EDTA tubes and PBMCs were isolated
by density gradient centrifugation on Histopaque®-1077
(Sigma Chemical Co., St. Louis, MO, USA).
The enzymatic activity of arginase was measured by
a colorimetric enzymatic assay as previously described.5
Arginase activity is expressed as mU per ml of blood.
Data were evaluated for statistical differences using a
two-tailed Mann-Whitney U test and for correlation using
Spearman’s rank test with GraphPad PRISM version 5.0
(Prism, San Diego, CA, USA).
3. Results
We subdivided our cohort of HIV+ patients into two
groups based on their CD4+ T cell count. Arginase activ-
ity in PBMCs isolated from 23 HIV+ patients with low
CD4+ T cell counts (≤350 cells/l) was signiﬁcantly
higher than that in 21 HIV+ patients with high CD4+ T
cell counts (median± SEM: 2.2±0.3 vs. 1.4±0.1 mU/ml
blood, respectively, P<0.001; Figure 1A). Moreover, we
founda statistically signiﬁcant inverse correlationbetween
arginase activity andCD4+ T cell count (r=−0.59, P<0.001).
In addition, our results show that high viral load correlates
with high arginase activity (r=0.43, P=0.003).
Toassess the impactofARTonarginaseactivitywestrat-
iﬁed the cohort into two groups. The 22 patients on ART
had a median (range) CD4+ T cell count of 475 (90–870)
and 21 of them had an undetectable plasma viral load (<1.7
log10 copies/ml). The 22 patients not on ART had a median
(range) CD4+ T cell count of 250 (0–800) and a median
(range) plasmaviral loadof 5.1 (2.66-5.67) log10 copies/ml.
Interestingly, a highly signiﬁcant inverse correlation
was found between CD4+ T cell count and PBMC arginase
activity in untreated but not in treated patients (untreated:
r=−0.676, P<0.001 vs. treated: r=−0.231, P=0.301;
Figures 1B and C). In addition, a positive association
between plasma viral load and PBMC arginase activity was
found in untreated patients (r=0.47, P=0.03). As 21 of the
22 patients receiving ART had viral loads below detection
limits association between arginase activity and viral load
in these patients could not be calculated.
These results show that both low CD4+ T cell count
and high viral load correlate with high arginase activity in
untreated but not treated HIV+ patients.
4. Discussion
Our study reveals that arginase activity is signiﬁcantly
higher in PBMCs from HIV+ patients with a low CD4+ T cell
count, compared with that in HIV+ patients with a high
CD4+ T cell count. Moreover, we found that in ART naïve
patients there is a signiﬁcant association between high
PBMC arginase activity and both of the principal markers≤350 cells/l; ***P<0.001. (B) Arginase activity and CD4+ T cell counts for
22 patients not on antiretroviral therapy (ART). (C) Arginase activity and
CD4+ T cell counts for 22 patients on ART.
of HIV disease progression, namely low CD4+ T cell count
and high plasma viral load. Therefore, we propose that the
higher arginase activity detected in PBMCs from advanced
untreated HIV+ patients may result in lower levels of L-
arginine, thereby causing dysregulation of T cell responses.
One potential consequence of L-arginine starvation is
altered T cell proliferation as it has been shown that
sub-physiological levels of L-arginine lead to G0-G1 cell
cycle arrest.4 A better understanding of the events result-
ing in the upregulation of arginase and the subsequent
downregulation of T cell responsiveness will improve our
understanding of the complex mechanisms leading to
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rogressive immune dysfunction in HIV/AIDS and may
rovide new targets to improve the efﬁcacy of therapy.
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